Members Login
Medical NewsEPG Search
Frequent Searches:
Browse Other Languages
Spanish Drug Data (España)
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
YouTube - Featured Content
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
![The NSCLCs account for 80% of all lung cancers and can be further subdivided into squamous-cell carcinoma, large-cell carcinoma and adenocarcinoma (which includes bronchioloalveolar-cell carcinoma [BAC]](/images/banners/nsclc.gif "The NSCLCs account for 80% of all lung cancers and can be further subdivided into squamous-cell carcinoma, large-cell carcinoma and adenocarcinoma (which includes bronchioloalveolar-cell carcinoma [BAC]")
Are you a Doctor or Healthcare Professional? Authorise Viewing
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
Change language
Current language database:
United Kingdom
Medicine information : FENDRIX
| Drug class description : | Hepatitis Vaccines |
| Generic Name : | Aluminium Phosphate - Monophosphoryl Lipid |
| Drug description : | Suspension for injection. Turbid white suspension. Upon storage, a fine white deposit with a clear colourless supernatant can be observed. |
| Presentation : | 1 dose (0.5 ml) of Fendrix contains: Hepatitis B surface antigen 1, 2, 3 20 micrograms 1adjuvanted by AS04C containing: - 3-O-desacyl-4'- monophosphoryl lipid A (MPL) 2 50 micrograms 2adsorbed on aluminium phosphate (0.5 milligrams Al3+ in total) 3produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology. |
| Indications : | Fendrix is indicated for active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes for patients with renal insufficiency (including pre-haemodialysis and haemodialysis patients), from the age of 15 years onwards. |
| Adult Dosage : | Posology Primary Immunisation schedule: A four dose schedule, with immunisations at the elected date, 1 month, 2 months and 6 months from the date of the first dose is recommended. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine. Booster dose: As pre-haemodialysis and haemodialysis patients are particularly exposed to HBV and have a higher risk to become chronically infected, a precautionary attitude should be considered i.e. giving a booster dose in order to ensure a protective antibody level as defined by national recommendations and guidelines. Fendrix can be used as a booster dose after a primary vaccination course with either Fendrix or any other commercial recombinant hepatitis B vaccine. Special dosage recommendation for known or presumed exposure to HBV: Data on concomitant administration of Fendrix with specific hepatitis B immunoglobulin (HBIg) have not been generated. However, in circumstances where exposure to HBV has recently occurred (e.g. stick with contaminated needle) and where simultaneous administration of Fendrix and a standard dose of HBIg is necessary, these should be given at separate injection sites. Method of administration Fendrix should be injected intramuscularly in the deltoid region. |
| Child Dosage : | See Adult Dosage |
| Contra Indications : | Hypersensitivity to the active substance or to any of the excipients. Hypersensitivity after previous administration of other hepatitis B vaccines. Subjects suffering from acute severe febrile illness. The presence of a minor infection such as a cold, is not a contraindication for immunisation. |
| Special Precautions : | Because of the long incubation period of hepatitis B, it is possible that patients could have been infected before the time of immunisation. The vaccine may not prevent hepatitis B infection in such cases. The vaccine will not prevent infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E or other pathogens known to infect the liver. As with any vaccine, a protective immune response may not be elicited in all vaccinees. A number of factors have been observed to reduce the immune response to hepatitis B vaccines. These factors include older age, male gender, obesity, smoking, route of administration, and some chronic underlying diseases. Consideration should be given to serological testing of those subjects who may be at risk of not achieving seroprotection following a complete course of Fendrix. Additional doses may need to be considered for persons who do not respond or have a sub-optimal response to a course of vaccinations. Since intramuscular administration into the gluteal muscle could lead to a suboptimal response to the vaccine, this route should be avoided. Fendrix should under no circumstances be administered intradermally or intravenously. Patients with chronic liver disease or with HIV infection or hepatitis C carriers should not be precluded from vaccination against hepatitis B. The vaccine could be advised since HBV infection can be severe in these patients: the Hepatitis B vaccination should thus be considered on a casebycase basis by the physician. Thiomersal (an organomercuric compound) has been used in the manufacturing process of this medicinal product and residues of it are present in the final product. Therefore, sensitisation reactions may occur. Appropriate medical treatment should always be readily available in case of rare anaphylactic reactions following the administration of the vaccine. |
| Interactions : | No data on the concomitant administration of Fendrix and other vaccines or with specific hepatitis B immunoglobulin have been generated. If concomitant administration of specific hepatitis B immunoglobulin and Fendrix is required, these should be given at different injection sites. As no data are available for the concomitant administration of this particular vaccine with other vaccines, an interval of 2 to 3 weeks should be respected. Pregnancy and lactation No clinical data on use during pregnancies are available with Fendrix. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Vaccination during pregnancy should only be performed if the risk-benefit ratio at individual level outweighs possible risks for the foetus. Adequate human data on use during lactation are not available. In a reproductive toxicity study in animals which included post-natal follow-up until weaning (see 5.3), no effect on the development of the pups was observed. Vaccination should only be performed if the risk-benefit ratio at individual level outweighs possible risks for the infant. |
| Adverse Reactions : | • Clinical trials involving the administration of 2476 doses of Fendrix to 82 pre-haemodialysis and haemodialysis patients and to 713 healthy subjects 15 years of age allowed to document the reactogenicity of the vaccine. Pre-haemodialysis and haemodialysis patients The reactogenicity profile of Fendrix in a total of 82 pre-haemodialysis and haemodialysis patients was generally comparable to that seen in healthy subjects. Adverse reactions reported in a clinical trial following primary vaccination with Fendrix and considered as being related or possibly related to vaccination have been categorised by frequency. Frequencies are reported as: Very common: >1/10 Common: >1/100, <1/10 Uncommon: >1/1000, <1/100 Rare: >1/10 000, <1/1000 Very rare: <1/10 000, including isolated reports Nervous system disorders: Very common: headache Gastrointestinal disorders: Common: gastrointestinal disorder General disorders and administration site conditions Very common: pain, fatigue Common: fever, redness, injection site swelling Unsolicited symptoms considered to be at least possibly related to vaccination were uncommonly reported and consisted of rigors, other injection site reaction and maculo-papular rash. Healthy subjects The reactogenicity profile of Fendrix in healthy subjects was generally comparable to that seen in pre-haemodialysis and haemodialysis patients. In a large double-blind randomised comparative study, healthy subjects were enrolled to receive a three dose primary course of Fendrix (N= 713) or a commercially available hepatitis B vaccine (N= 238) at 0, 1, 2 months. Fendrix was generally well tolerated. The most common adverse events reported were local reactions at the injection site. Vaccination with Fendrix induced more transient local symptoms as compared to the comparator vaccine, with pain at the injection site being the most frequently reported solicited local symptom. However, solicited general symptoms were observed with similar frequencies in both groups. Adverse reactions reported in a clinical trial following primary vaccination with Fendrix and considered as being at least possibly related to vaccination have been categorised by frequency. Infections and infestations: Rare: viral infection Metabolism and nutrition disorders: Rare: thirst Psychiatric disorders: Rare: nervousness Nervous system disorders: Common: headache Rare: vertigo Gastrointestinal disorders: Common: gastrointestinal disorder Muskuloskeletal and connective tissue disorders: Rare: back pain, tendinitis General disorders and administration site conditions Very common: fatigue, pain, redness, injection site swelling Common: fever Uncommon: other injection site reaction Rare: allergy, asthenia, hot flushes, rigors No increase in the incidence or severity of these undesirable events was seen with subsequent doses of the primary vaccination schedule. No increase in the reactogenicity was observed after the booster vaccination with respect to the primary vaccination. Allergic reactions, including anaphylactoid reactions, may occur very rarely. • Experience with hepatitis B vaccine: Following widespread use of hepatitis B vaccines, in very rare cases, syncope, paralysis, neuropathy, neuritis (including Guillain-Barré syndrome, optic neuritis and multiple sclerosis), encephalitis, encephalopathy, meningitis and convulsions have been reported. The causal relationship to the vaccine has not been established. |
| Manufacturer : | GlaxoSmithKline |
| Drug Availability : | (POM) |
Free registration to access disease diagnosis, patient management, physician tools.
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org